RESEARCH MONOGRAPH · KDC-MN-1316
Articaine
Articaine (Ultracain, Septocaine) is the dominant dental local anesthetic in much of Europe and increasingly in North America, structurally distinct from other amide locals in carrying both an amide and a methyl ester linkage on a thiophene ring. The methyl ester is rapidly hydrolyzed by plasma esterases to the inactive articainic acid metabolite, producing the shortest plasma half-life of any amide local anesthetic (about 25 minutes). That truncates systemic exposure during repeated dental infiltration. The thiophene ring confers enhanced bone diffusion, supporting the clinical perception that articaine produces effective infiltration anesthesia of mandibular molar teeth without requiring a full inferior alveolar nerve block. Sold as 4 percent solution with epinephrine 1:100,000 or 1:200,000. The principal safety considerations are mild methemoglobinemia risk and case reports of paresthesia after IAN block. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
Amide local anesthetic with thiophene ring (dental)
The dominant dental local anesthetic in much of Europe and increasingly in North America, distinguished by a thiophene ring enabling rapid plasma esterase hydrolysis.
Abstract
Articaine (methyl 4-methyl-3-(2-propylaminopropanoylamino)thiophene-2-carboxylate; CAS 23964-58-1; molecular formula C13H20N2O3S; molecular weight 284.38) is an amide local anesthetic developed by Hoechst in the 1970s and introduced in Germany in 1976 (Ultracain, Septocaine in North America). The compound is structurally distinct among amide local anesthetics in carrying both an amide and a methyl ester linkage on a thiophene ring rather than the dimethylphenyl ring of lidocaine and the pipecoloxylidide family. The methyl ester is rapidly hydrolyzed by plasma esterases to the inactive articainic acid metabolite (plasma half-life approximately 25 minutes, shorter than any other amide), which truncates systemic exposure and reduces accumulation risk during dental procedures requiring repeated infiltration. The thiophene ring confers enhanced bone diffusion, supporting the clinical perception that articaine produces effective infiltration anesthesia of mandibular molar teeth without requiring inferior alveolar nerve block in many cases (a clinical advantage that makes articaine the dominant dental anesthetic in much of Europe). Mechanism is voltage-gated sodium channel block; potency is approximately 1.5-fold that of lidocaine on infiltration. Articaine is sold as a 4 percent solution with epinephrine 1:100,000 or 1:200,000. The principal safety considerations are the same methemoglobinemia risk noted for prilocaine (articaine generates methemoglobin-inducing metabolites though at lower doses than prilocaine, the clinical risk is correspondingly low) and case reports of paresthesia after inferior alveolar nerve block.
Mechanism of action
Voltage-gated sodium channel block. Plasma esterase hydrolysis of methyl ester drives short systemic half-life. Thiophene ring enhances bone diffusion.
Reported research dose ranges
Reported research dose ranges vary across the published literature.
References
- Malamed SF, et al. Articaine hydrochloride: a study of the safety. J Am Dent Assoc 2001.
- Yapp KE, et al. Articaine: a review of the literature. Br Dent J 2011.
- Kammerer PW, et al. Articaine versus lidocaine in maxillary infiltration anesthesia. J Am Dent Assoc 2012.
Read the full monograph
Available as a research-use-only PDF download.
The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.